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Abstract
Primrose syndrome (PS; MIM# 259050) is characterized by intellectual disability (ID),
macrocephaly, unusual facial features (frontal bossing, deeply set eyes, down-slanting
palpebral fissures), calcified external ears, sparse body hair and distal muscle wasting.
The syndrome is caused by de novo heterozygous missense variants in ZBTB20. Most
of the 29 published patients are adults as characteristics appear more recognizable
with age. We present 13 hitherto unpublished individuals and summarize the clinical
and molecular findings in all 42 patients. Several signs and symptoms of PS develop
during childhood, but the cardinal features, such as calcification of the external ears,
cystic bone lesions, muscle wasting, and contractures typically develop between
10 and 16 years of age. Biochemically, anemia and increased alpha-fetoprotein levels
are often present. Two adult males with PS developed a testicular tumor. Although
PS should be regarded as a progressive entity, there are no indications that cognition
becomes more impaired with age. No obvious genotype-phenotype correlation is pre-
sent. A subgroup of patients with ZBTB20 variants may be associated with mild, non-
specific ID. Metabolic investigations suggest a disturbed mitochondrial fatty acid
oxidation. We suggest a regular surveillance in all adult males with PS until it is clear
whether or not there is a truly elevated risk of testicular cancer.
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1 | INTRODUCTION
Primrose syndrome (PS; MIM# 259050) is an infrequently described
condition characterized by increased postnatal growth in height and
head circumference, unusual facial features (frontal bossing, deeply
set eyes, down-slanting palpebral fissures), cognitive deficit associated
with autism spectrum disorder, and ectopic calcifications.1 With age,
distal muscle atrophy, hearing loss, cataract, sparse body hair, and a
disturbed glucose metabolism can become clear.2-18 Until recently
most reported affected individuals have been adults as the phenotype
may become more easily recognizable over time.
PS is mostly caused by de novo heterozygous missense vari-
ants in the N-terminal portion of the DNA binding domain of
ZBTB20 (MIM* 606025), a transcriptional repressor.10 Two patients
carrying truncating variants or small deletions have also been
reported.6,14 The protein is a member of the broad complex
tramtrack bric-a-brac (BTB) zinc-finger (ZnF) family and is character-
ized by an N-terminal BTB domain that is involved in protein-
protein interaction, and five C2H2 zinc fingers at the C-terminus
mediating protein binding to regulatory sites within promoters of
target genes.19-22 ZBTB20 acts as a regulator of neurogenesis, fetal
liver development, somatic growth, detoxification and glucose
metabolism.23-25 Thus far, all ZBTB20 variants causing PS have
been missense variants that affect amino acid residues in the first
and second ZnF motifs.10,11
Here we summarized the collective data from 42 patients with
PS, 13 of whom have not been reported before, present the clinical,
biochemical and molecular characteristics, and emphasize their evolu-
tion over time.
2 | SUBJECTS AND METHODS
2.1 | Subjects
The present series were gathered by contacting authors who have
previously published on PS or because collaborators contacted one of
us (RCH) because of his experience with PS. Data were collected
through a table specifically designed for the study (Supplemental data
Table S1). Clinical pictures, results of formal testing of cognitive devel-
opment, and results of biochemical tests were also gathered. No bio-
chemical or genetic studies were performed specifically for the
present study. We gathered data from 29 patients reported previ-
ously1-18 and 13 hitherto unpublished patients. One stillbirth was also
included. Intellectual disability (ID) was classified as mild/moderate-
severe based on neuropsychological consultations; IQ scores were
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included if available. The study was approved by the Medical Ethics
Committee of the Amsterdam UMC (NL45451.018.13).
2.2 | Molecular analyses
Molecular studies were performed either by whole-exome sequencing
(WES) using a panel aimed at detecting variants in genes known to
cause ID if mutated, or by Sanger sequencing. In 32 patients, a
ZBTB20 variant was detected using panel sequencing for ID, after
which the clinical diagnosis was established. In four patients, the diag-
nosis was clinically based and the ZBTB20 variant was subsequently
detected by Sanger sequencing. In one patient, the diagnosis was
established based on SNP array. In five patients reported in literature,
no information on methods of molecular analysis was available (all
these patients showed normal karyotype).
3 | RESULTS
The study included 22 males and 20 females, varying in age between
9 months and 49 years. The mean and the median age at diagnosis
were 17.3 ± 15.4 years and 11.0 ± 15.4 years. The main clinical char-
acteristics of the study participants are summarized in Tables 1 and 2
and illustrated in Figures 1 and 2 and Figure S1. The data in the tables
are shown separately for children (0-16 years) and adults (>16 years).
Detailed information for each patient is available in Table S1, see Sup-
plement. In the text, only data for which information is not reported in
the tables are discussed. Single patient number is indicated between
brackets if specific findings are mentioned.
3.1 | Growth
The mean duration of pregnancy was 38.8 ± 2.0 weeks. Three preg-
nancies (P5, P21, and P28) were complicated by oligohydramnios, one
pregnancy resulted in intrauterine demise (P28). Postnatal growth in
height and weight is usually between the 50th and 90th centile but in
males sometimes is >98th centile (Supplemental Figure 1-2).
3.2 | Development and behavior
IQ score was available in seven patients (P7, P9, P21, P33-36; six chil-
dren, IQ 25-77, one adult, IQ 25). Infrequent findings included atten-
tion deficit hyperactivity disorder (ADHD) (P9, P36, P37) and delayed
speech (P7, P8). One child showed hyperphagia (P32), one adult
patient also showed schizophrenia (P42). Patients' intellectual
TABLE 1 Growth, development, and behavior in the 42 individuals with Primrose syndrome
Children Adults All
n = 29 n = 13 n = 42
Growth at birth
Length (cm) 49.7 ± 3.60
Length > 2SD 1/22
Weight (kg) 3.19 ± 0.64
Weight > 2SD 3/29
Head circumference (cm) 35.91 ± 2.25
Head circumference > 2SD 9/22
Postnatal growth
Mean age at last clinical evaluation (y) 7.74 ± 4.22 37.38 ± 10.34 17.80 ± 15.6
Height (cm) 125.83 ± 29.33 177.50 ± 10.71
Height > 2SD 3/25 (12%) 0/9 (0%) 3/34 (9%)
Weight (kg) 31.91 ± 22.45 72.80 ± 16.09
Weight > 2SD 6/25 (24%) 0/6 (0%) 6/31 (19%)
Head circumference (cm) 54.71 ± 3.69 58.75 ± 2.46
Head circumference > 2SD 21/26 (81%) 8/12 (67%) 29/38 (76%)
Development
Intellectual disability mild 5/27 (19%) 2/13 (15%) 7/39 (18%)
Intellectual disability moderate-severe 22/27 (81%) 11/13 (85%) 33/39 (85%)
Behavior
Autism 16/24 (67%) 4/9 (44%) 20/33 (61%)
Self-injurious behavior 7/19 (37%) 4/7 (57%) 11/26 (42%)
Sleep disturbances 8/19 (42%) 2/7 (29%) 10/26 (38%)
Note: Only data of at term born newborns (38-42 wk) have been used.
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function seems not to change over time (Figure 2A). Insufficient data
were available to evaluate reliably whether behavioral problems were
progressive with time or not.
3.3 | Morphological signs
No morphological sign is present in all affected individuals (Table 2),
and the phenotype is variable indeed (Figure 1). Infrequently reported
findings included cleft palate (P37, P38) and short philtrum (P21, P22,
P31, P34, and P35). Four children also showed hypertrichosis (P2,
P17, P28, and P29).
3.4 | Neuromuscular findings
Muscle wasting was first noticed at age 11 years and shows a clear
increase with age (Table 2; Figure 2B). A muscle biopsy was available
TABLE 2 Clinical features of the 42
individuals with Primrose syndrome
HPO ID Children Adults All
Clinical sign N = 29 N = 13 N = 42
Morphology
Brachycephaly 0000248 8/18 (44%) 5/9 (56%) 13/27 (48%)
Frontal bossing 0002007 15/20 (75%) 7/9 (78%) 22/29 (76%)
Ptosis 0000508 10/18 (56%) 10/10 (100%) 20/28 (71%)
Downslanted palpebral fissures 0000494 11/22 (50%) 7/12 (58%) 18/34 (53%)
Deeply set eyes 0000490 16/21 (76%) 10/11 (91%) 26/32 (81%)
Highly arched palate 0002705 7/17 (41%) 2/6 (33%) 9/23 (39%)
Torus palatinus 189 700 1/16 (6%) 6/11 (55%) 7/27 (26%)
Large jaw 0040309 8/17 (47%) 8/11 (73%) 16/28 (57%)
Large ears 0000400 14/25 (56%) 10/11 (91%) 24/36 (67%)
Calcification of ears 0005103 2/17 (12%) 12/12 (100%) 14/28 (50%)
Neuromuscular findings
Seizures 0001250 2/20 (10%) 4/9 (44%) 6/29 (21%)
Ataxia 0001251 6/18 (33%) 2/5 (40%) 8/23 (35%)
Hypotonia 0001252 21/25 (84%) 5/9 (56%) 26/34 (76%)
Distal muscle wasting 0003693 1/22 (5%) 11/11100%) 12/33 (36%)
Flexion contractures 0001371 5/24 (21%) 8/8 (100%) 13/31 (42%)
Delayed myelination 0012448 1/23 (4%) 2/11 (18%) 3/34 (9%)
Brain calcification 0002514 3/23 (13%) 1/11 (9%) 4/34 (12%)
Corpus callosum anomaly 0001273 11/23 (48%) 4/11 (36%) 15/34 (44%)
System involvement
Cataract 0000518 0/20 (0%) 6/10 (60%) 6/30 (20%)
Strabismus 0000486 10/21 (48%) 0/10 (0%) 10/31 (32%)
Hearing loss 0000365 21/27 (78%) 12/13 (92%) 33/40 (83%)
Scoliosis 0002650 9/23 (39%) 6/10 (60%) 15/33 (45%)
Cystic bone lesions 0012062 0/9 (0%) 5/9 (56%) 5/18 (28%)
Decreased BMD 0004349 3/8 (38%) 6/9 (67%) 9/17 (53%)
Hip dysplasia 0001385 1/17 (6%) 4/8 (50%) 5/25 (20%)
Thin nail 0001816 6/20 (30%) 4/7 (57%) 10/27 (37%)
Sparse body hair 0002231 11/12 (92%) 11/12 (92%)
Delayed puberty 0000823 3/11 (27%) 3/11 (27%)
Cryptorchidism 0000028 5/10 (50%) 2/6 (33%) 7/16 (44%)
Tumors 0002664 0/15 (0%) 2/9 (22%) 2/24 (8%)
Diabetes mellitus 0000819 2/16 (13%) 6/9 (67%) 8/25 (32%)
Anemia 0001903 4/16 (25%) 1/5 (20%) 5/21 (24%)
Elevated serum AFP levels 0006254 4/11 (36%) 5/7 (71%) 9/18 (50%)
Abbreviations: AFP, alpha-fetp protein; BMD, bone mineral density; HPO ID, human phenotype ontology identifier.
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in patient 23 only, which demonstrated neurogenic atrophy. Contrac-
tures were first noticed at age 10 years and became more prominent
with age as well. Hypertonia probably due to spasticity, was present
in two patients (P25, P42) and was recognized first in adulthood.
Infrequent findings included joint hypermobility of the upper limbs
(P17, P26, P30), and Chiari malformation (P30).
3.5 | Systemic findings
Someother findings show a difference in occurrence with age as
well (Table 2), although some can occur at an early age as well.
Dysplastic hip joint changes, cystic bone lesions, and cataract
were found only in adults. Infrequent reported findings included
F IGURE 1 Features from selected individuals with Primrose syndrome. (A) Faces from youngest to oldest at age 1.5 years (A), 2.5 years (B),
3 years (C), 4 years (D), 4 years (E), 5 years (F), 6 years (G), 8 years (H), 9 years (I), 11 years (J), 12 years (K), 13 years (L), 18 years (M), 31 years (N),
33 years (O), and 53 years (P). The patient identification number is indicated underneath the panels. (B) Other clinical features include alobar
calcified ear (1), calcified ear on X-ray (2), incomplete extension of fingers and small nails (3), joint hypermobility (4), distal muscle wasting in an
adult (5), markedly small and thin nails (6), and malformed callosal body (7) [Colour figure can be viewed at wileyonlinelibrary.com]
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reduced tear production (P2, P13), microphthalmia (P25, P38),
unilateral blindness due to glaucoma (P2), kyphosis (P20, P32,
P39), hyperlordosis (P32), pectus abnormalities (P10, P14),
pulmonary artery stenosis in an adult patient (P16), small penis
(P37), hypothyroidism (P3, P5, P18), and GH deficiency (P10,
P37). Baseline adrenal cortex hormones were also checked in four
patients, with normal results. Alpha-fetoprotein (AFP) levels
showed that levels were typically elevated but not in all affected
individuals, and did not show a marked change over time
(Figure 2C). One patient showed selective IgG2 deficiency (P31).18
One patient developed a testis carcinoma at 27 years and a (fatal)
seminoma in the other testis at 40 years of age5 Another male
developed a germ cell tumor at 28 years and also a seminoma at
that age.9
3.6 | Metabolic investigations
Plasma amino acids were investigated in nine patients and tested nor-
mal. Plasma acylcarnitines were available in four patients showing
increased C2, C4OH, C5OH, C6OH, C14, and C14:2 levels in two of
them. Mild ketonuria was found in four patients, and two of these
four (P14, P21) also showed mild dicarboxylic aciduria, together with
increased ethylmalonic acid and glutaric acid excretion.
F IGURE 2 Changes with age of
cognition, muscle wasting, and serum
alpha-fetoprotein (AFP) in individuals with
Primrose syndrome. A, Cognition. No
evident correlation. B, Muscle wasting;
data are presented based on age of first
appearance. Increase with age evident. C,
AFP serum levels. Each symbol represents
a single individual; course over time in
single patients is depicted if available.
Elevated levels in almost every individual;
no clear change with age in a single
individual
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3.7 | Molecular testing
ZBTB20 variants for all reported individuals are tabulated in Table 3, and
depicted in Figure 3. None was present in the public database gnomAD
(Table S2). All variants were either missense changes or insertion/dele-
tions, acting as a frameshift, and have been classified as class 4 and class
5 according to the criteria of the American College of Medical Genetics.
No variants were detected in the BTB site or in the distal part of the
ZnF_C2H2 site in individuals with a phenotype-fitting PS. No indications
for mosaicism were detected in any patient. In all patients in whom one
or both parents were available (n = 26), the variant was found to be de
novo. No familial occurrence has been reported. Mean paternal age at
birth was 33.9 ± 7.5 years; mean maternal age at birth was 30.3 ± 4.9.
3.8 | Genotype-phenotype correlation
The genotype was available for 38 patients (Table 3). Obviously the
phenotype in the four patients reported before the causative gene
was found, was more severe due to ascertainment bias. No clear
genotype- phenotype correlation was detected. Some individuals
with a variant in exon 1 (P6: c.1768A>C; P9: c.1794C>G) and in
exon 5 (P34: c.1844_1846del; P19: c.1861C>T) showed a less
severe ID, and some also only a limited number of the other char-
acteristics of PS. However, other patients carrying variants in
nearby base pairs showed the classical phenotype. The difference
in age of the affected individuals and the progressive nature of the
findings further hamper to correlate phenotype and genotype
reliably.
4 | DISCUSSION
We present a series of hitherto unpublished individuals with PS and
summarize the findings of these individuals and those that have been
reported in literature. The present study confirms that PS can present
as an overgrowth syndrome with respect to brain growth (71%), but
increased growth in height and weight is less marked and present in a
minority of the patients (21%). Indeed, some females grow below the
third centile for height and weight. The growth pattern is already pre-
sent at birth and the subsequent overgrowth is non-progressive.
The cardinal findings of PS are the ID (mild 16%, moderate-severe
84%), mildly increased growth (height and weight between 50th and
90th centile, macrocrania 78%), and as most characteristic signs the
calcified external ears, sparse body hair, bone dysplasia, and distal
muscle wasting. The calcification of the ears, cataract, torus palatinus,
cystic bone lesions and muscle wasting with subsequently contracture
formation are clearly age-related and become often only apparent in
puberty or thereafter, so percentages differ in the various age groups.
Cognition does not seem to decline with age, although sufficiently
F IGURE 3 Schematic overview of the ZBTB gene and localization of mutations. It is noteworthy that patient carrying p.Gln209Arg mutation
showed no macrocephaly and no ID. Autism and self-injurious behavior were recorded [Colour figure can be viewed at wileyonlinelibrary.com]
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detailed studies to conclude this with certainty are missing. Hearing
loss is also common both in children and adults, mostly presenting as
sensorineural hearing loss.
The progression in signs and symptoms with age may point to a
metabolic disturbance. Biochemically, unexplained anemia, disturbed
glucose metabolism, and increased AFP levels are cardinal features of
PS. Further metabolic investigations demonstrated abnormal
acylcarnitine and urine organic acid profiles in some PS individuals,
including increased excretion of dicarboxylic acids, ethylmalonic and
glutaric acids. In one individual (P8), this pattern became more abnor-
mal with age. Over time, this patient showed progressive lipo-
dystrophy and developed muscle wasting with limb atrophy by
11 years of age; at that time, Oral Glucose Tolerance test also showed
impaired glucose tolerance. The findings suggest disruption of the
mitochondrial fatty acid oxidation. One may speculate that this is
linked to pleiotropic effects of ZBTB20 on lipid and glucose metabo-
lism.19,25 Mitochondrial dysfunction has been reported in Zbtb20
knock-out mouse.26 Mitochondrial dysfunction has also been involved
in the development of muscle atrophy27 and insulin-resistance,28 type
2 diabetes,29 and cataract,30 but at the present, there is no proof that
these signs can be explained in PS individuals due to mitochondrial
malfunctioning. More detailed analyses of mitochondrial functioning
are warranted.
Increased AFP levels constitute a remarkable sign in PS. It has
been proposed that mutated ZBTB20 disrupts the AFP repression
resulting in AFP increase and overgrowth. AFP levels appeared >2 SD
higher than reference values by age31 during the first months of life
and progressively decreased with age. Among the presently reported
males, two adults developed a testis tumor. No female developed
neoplasm. Despite reports of ZBTB20 expression being associated
with tumorigenesis, including gastric cancer21 and hepatocellular
carcinoma,32 it remains unclear whether an increased risk of malignan-
cies is part of this syndrome.
To evaluate whether ZBTB20 variants are more common in men
with testicular germ cell tumor (TGCT), we interrogated WES data
from lymphocyte-derived DNA from 919 TGCT cases of Western
European ancestry (comprising 306 familial and 613 unselected TGCT
cases) and 1609 healthy controls of Western European ancestry from
the UK 1958 Birth Cohort, all analyzed via the same pipeline.33,34 We
compared between TGCT cases and healthy controls, the frequency
of high quality, rare (minor allele frequency [MAF] < 0.01) non-
synonymous variants. In the TGCT series, three rare non-synonymous
ZBTB20 variants [p.(Thr514Ala), p.(Ala693Val), and p.(Gly712Val)]
were identified in the constitutional DNA of men with familial TGCT
and one in a man with non-familial TGCT [p.(Gly712Val)]. These men
developed their seminoma or teratoma at ages 28, 28, 32, and
33 years, respectively. No further data regarding serum biomarkers or
clinical phenotype were available for these patients. No rare non-
synonymous ZBTB20 variants were detected in 1609 healthy controls.
Paired tumor germline WES data were available for an additional
179 TGCT cases: no ZBTB20 variants were detected in the constitu-
tional or tumor DNA.35 Thus, the frequency of germline ZBTB20
mutation in TGCT cases would appear elevated (4/1098 in cases,
0/1609 in controls, Pexact < .05). Still, the absolute risk of TGCT is low
(1 in 200 in Western European males, lower in other ethnicities) and
TGCT typically has an excellent outcome.36 The two males with PS
who developed testicular tumors have died because of their tumors.
There is no recognized protocol for TGCT surveillance established as
effective for subpopulations at significant elevation of risk (such as
family history, prior contralateral disease, or cryptorchidism). In addi-
tion, self-examination is not feasible in most men with
PS. Accordingly, families and other caregivers of men with PS should
be alerted to the possible modest elevation in relative risk of TGCT,
reassured as to the low absolute risk, and advised regarding symptom
awareness and testicular examination by caregivers.
There is no evident genotype-phenotype correlation in the pre-
sent series. However, numbers are small, and it may still be that if a
larger series can be evaluated this will become clear.
A dominant-negative effect of missense variants has been previ-
ously hypothesized.10 Cleaver et al provided very limited information
on an individual with a de novo c.505G>C [p.(Glu169Gln)] variant in
whom pathogenicity remained uncertain, presumably because the
phenotype did not resemble PS.16 We follow a patient (not included
in the present series) with ZBTB20 variant c.1775A>G [p.(Asn519Ser)]
detected by WES because of unexplained mild ID. This adult woman,
age 39 years, has macrocephaly but otherwise none of the character-
istic signs or symptoms of PS is present. She did show short stature
and an unusual face. No other potentially pathogenic variants have
been detected by WES, and the ZBTB20 variant is absent in her par-
ents. It remains uncertain whether the variant is pathogenic. If so, it
indicates that ZBTB20 variants can lead to ID and brain anomalies
without the other characteristics of PS. In this respect, it may be of
interest that two individuals with nearby located variants (P6:
c.1768A>C; P9: c.1794C>G) show a relatively mild phenotype with
less severe ID as well. Data suggest that patients with frameshift vari-
ants may show a milder phenotype. However, the small number of
patients and limited data hamper reliable conclusions on genotype-
phenotype correlations.
A major limitation of the present study is its retrospective nature.
Early clinical data were sometimes lacking as the clinical suspicion for
PS raised later in life. Additionally, several patients came to the atten-
tion of a physician only as adults, hampering a complete early clinical
history.
We conclude that PS is an established clinical entity that is recog-
nizable in adults but more difficult to recognize in infants and children.
In a clinically suspicious child checking the AFP levels can be useful.
The manifestations are progressive, and repeated evaluation for ane-
mia, diabetes, and osteoporosis are indicated. At the present, there is
no clear indication that cognition shows a decline with time as well.
There may be an increased risk to develop testis tumors, and regular
follow-up for this from puberty onward seems indicated.
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